GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Passage Bio Inc.
Pasage Bio is a biotech company specializing in gene therapy for rare CNS diseases. Its stock price represents a venture bet on a breakthrough in this complex field. The chart reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Neuro
Passage Bio is a biotech company focused on developing gene therapies for the treatment of rare monogenic diseases of the central nervous system. We've categorized it under the "Neurology" category, and the chart below shows how investors view the prospects for this breakthrough medical field.
Broad Market Index - GURU.Markets
Passage Bio is a biopharmaceutical company developing gene therapies for rare monogenic diseases of the central nervous system. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
PASG - Daily change in the company's share price Passage Bio Inc.
For Passage Bio, Inc., a gene therapy company, daily volatility reflects sensitivity to clinical trial data for rare neurological diseases. This metric is key for assessing risks in this innovative field.
Daily change in the price of a set of shares in a market segment - Neuro
Passage Bio, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with PASG, which focuses on CNS gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Passage Bio is a biotech company specializing in gene therapy for rare diseases of the central nervous system. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Passage Bio Inc.
For Passage Bio, Inc., the year-over-year trend is a story of developing gene therapies for rare CNS diseases. Its 12-month market cap is entirely dependent on clinical trial data. Success in its programs for treating dementia and other severe conditions could offer new hope for patients, but the risks in this area are extremely high.
Annual dynamics of market capitalization of the market segment - Neuro
As an early-stage biotech, Pasithea is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs for neurological diseases. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Passage Bio, a gene therapy company, is a classic example of a company whose fate is decided in the lab, not the market. Its year-over-year performance relative to the S&P 500 tells a story not about economics but about investors' faith in the success of clinical trials. Any news of progress or failure can send the stock plummeting or plummeting, defying any market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Passage Bio Inc.
Passage Bio is a company developing gene therapies for rare CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its flagship programs are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the biotech sector, particularly gene therapy. For Passage, which focuses on CNS diseases, it's the backdrop. Its volatile movements demonstrate how clinical trial successes and failures influence investor sentiment across the industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Passage Bio is a biotech company developing gene therapy for rare diseases of the central nervous system. Its value depends almost entirely on the results of clinical trials. The broader market has little impact on Passage Bio shares; their fate is decided in laboratories and clinics, which can lead to sharp movements counter to the market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Passage Bio Inc.
Passage Bio, a gene therapy company developing treatments for rare monogenic diseases of the central nervous system (CNS), is experiencing high volatility. Weekly stock price movements are a direct response to the release of clinical trial data and regulatory decisions that determine the fate of its developments.
Weekly dynamics of market capitalization of the market segment - Neuro
Passage Bio operates in the highly competitive gene therapy sector, where investor sentiment drives the overall sentiment. Any significant success or failure in the industry affects everyone's risk appetite. The chart will show whether PASG is following the general flow of biotech speculation or whether its unique scientific news is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Passage Bio, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how PASG shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
PASG - Market capitalization of the company Passage Bio Inc.
Passage Bio's stock chart is a focused bet on gene therapy for rare diseases of the central nervous system. This biotech's valuation is a rollercoaster ride, with every clinical trial result potentially leading to a dramatic rise or fall. It's a story of high risk and enormous potential reward.
PASG - Share of the company's market capitalization Passage Bio Inc. within the market segment - Neuro
Passage Bio is a biotech company focused on developing gene therapies for the treatment of rare monogenic diseases of the central nervous system. Its market share is based on its pipeline of candidates. The chart shows how the market views its scientific progress and the risks associated with this highly complex area of medicine.
Market capitalization of the market segment - Neuro
Passage Bio is a gene therapy company for rare neurological diseases. The chart below shows the market capitalization of the neurological sector. This represents the valuation of a complex and risky business, where one successful drug can change everything.
Market capitalization of all companies included in a broad market index - GURU.Markets
Pasage Bio is a biopharmaceutical company developing gene therapies for rare diseases of the central nervous system. Its market capitalization reflects the hope for a breakthrough in this complex field. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
PASG - Book value capitalization of the company Passage Bio Inc.
Passage Bio's book value is capital for gene therapy. Its foundation consists of licenses from the University of Pennsylvania for rare CNS diseases and funds for very expensive clinical trials. The chart below shows how the company uses its financial resources in its quest to develop breakthrough drugs.
PASG - Share of the company's book capitalization Passage Bio Inc. within the market segment - Neuro
Passage Bio, which develops gene therapy, has key assets in the form of R&D laboratories and manufacturing partnerships. The S_BCap_Seg graph shows its share of scientific infrastructure, reflecting its focus on research.
Market segment balance sheet capitalization - Neuro
Passage Bio is developing gene therapy for rare CNS diseases. Its value lies in its unique scientific platform and development pipeline. A book value chart shows that its assets are almost entirely intangible, which is typical for advanced genetic medicine.
Book value of all companies included in the broad market index - GURU.Markets
Passage Bio's book value represents capital focused on CNS gene therapy. The company's assets include the rights to develop several drugs for rare neurological diseases and the financial resources for their clinical testing. The chart shows the size of its resources dedicated to delivering the right genes to the brain.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Passage Bio Inc.
Passage Bio develops gene therapy for rare diseases of the central nervous system. The company's book value is primarily cash. Its market capitalization is a valuation of its research programs and the hope that its drugs will provide breakthroughs in the treatment of severe genetic disorders.
Market to book capitalization ratio in a market segment - Neuro
Passage Bio is a company specializing in gene therapy for rare CNS diseases. Its value is determined by its pipeline. The chart shows how the market evaluates the scientific potential and risks of its clinical programs compared to its book value (primarily cash).
Market to book capitalization ratio for the market as a whole
Passage Bio is a biotech company specializing in gene therapy for rare diseases of the central nervous system. Its value is based on the potential of its scientific platform. The chart shows how the market valuation reflects investor faith in scientific breakthroughs, creating a huge gap with its book value.
Debts of the company, segment and market as a whole
PASG - Company debts Passage Bio Inc.
Passage Bio, a company developing gene therapies for rare CNS diseases, uses debt to finance its expensive clinical programs. This chart shows how it has raised significant funds to advance its drug candidates through the complex and lengthy stages of clinical trials.
Market segment debts - Neuro
Passage Bio is a clinical-stage biotech company specializing in gene therapy for rare diseases of the central nervous system. These studies are extremely expensive, requiring hundreds of millions of dollars. This chart shows its financial health and ability to fund its complex and long-term clinical programs to bring drugs to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Passage Bio Inc.
Passage Bio specializes in gene therapy for rare diseases of the central nervous system. This chart shows whether the company is raising debt financing. For a business like this, where the journey from lab to patient takes years and costs hundreds of millions, any debt is a critical risk factor that investors should carefully consider.
Market segment debt to market segment book capitalization - Neuro
Passage Bio is a company specializing in gene therapy for rare diseases of the central nervous system. This biotech chart illustrates how the industry funds long and risky research. It provides context for assessing the company's financial strategy in one of the most complex areas of medicine.
Debt to book value of all companies in the market
Passage Bio specializes in gene therapy for rare diseases of the central nervous system. This requires colossal investment. The debt-to-book value ratio reflects the availability of capital in the biotech sector, which is critical for funding Passage Bio's long-term clinical trials.
P/E of the company, segment and market as a whole
P/E - Passage Bio Inc.
Passage Bio is a gene therapy company focused on treating rare neurological diseases. This chart reflects the high stakes of this medical field. Its dynamics depend entirely on the results of clinical trials. Success can lead to the development of a life-changing drug and explosive growth, while failure can lead to complete devaluation.
P/E of the market segment - Neuro
Passage Bio, Inc. operates in the gene therapy sector. This chart shows the average price-to-earnings ratio (P/E) for this cutting-edge industry. Comparing the company's P/E to this ratio allows us to understand how highly the market values its focus on rare neurological diseases compared to other companies engaged in genetic engineering for other purposes.
P/E of the market as a whole
Passage Bio is a company specializing in gene therapy for rare monogenic diseases of the central nervous system. It was founded in partnership with the University of Pennsylvania. This chart illustrates the risk appetite in biotech. The company's valuation depends on the success of its clinical programs and its ability to overcome the challenges associated with delivering gene therapy to the brain.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Passage Bio Inc.
Passage Bio is a gene therapy company focused on treating rare diseases of the central nervous system. The chart reflects investor expectations for future revenue, which are entirely dependent on the clinical trial results of its drug candidates. This is a high-risk, high-reward opportunity.
%20P%2FE%20Passage%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Passage-Bio-Inc.&v=1772567363671 "Chart of the company's future (projected) P/E Passage Bio Inc.")
Future (projected) P/E of the market segment - Neuro
Passage Bio is a gene therapy company focused on developing life-changing treatments for rare monogenic diseases of the central nervous system. This chart displays its future profitability expectations, allowing us to assess how highly the market values its scientific potential and the risks associated with this cutting-edge field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772567363758 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Passage Bio is a biotech company developing gene therapies for rare neurological diseases. It's a high-risk business, where value is determined by investors' faith in the science and potential of its drugs, not by current market conditions, as reflected in this chart.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772567363812 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Passage Bio Inc.
Passage Bio is a biopharmaceutical company developing gene therapies for the treatment of rare monogenic diseases of the central nervous system (CNS). Its financial performance reflects significant investments in clinical trials. This chart illustrates the capital expenditures required to bring complex and expensive treatments to market.
Profit of companies in the market segment - Neuro
Passage Bio, Inc. is a genetic therapeutics company focused on developing drugs to treat rare monogenic diseases of the central nervous system (CNS). This chart shows the profitability of the neurology segment. The company's ongoing clinical trial costs impact overall profitability, but its success could bring breakthrough treatments to market.
Overall market profit
Passage Bio is a biotechnology company focused on developing gene therapies for rare diseases of the central nervous system. Its value and future are determined by scientific discoveries and the success of its clinical programs. This chart illustrates general economic cycles, with Passage Bio operating at the forefront of genetics, creating value independently of the market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Passage Bio Inc.
Passage Bio is a gene therapy company specializing in rare monogenic diseases of the central nervous system (CNS). This chart reflects analysts' expectations for future earnings, based on the potential of its drug candidates. Sharp revisions to forecasts are often driven by news of clinical trials, which will determine the company's future in this cutting-edge field.
%20profit%20of%20the%20company%20Passage%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Passage-Bio-Inc.&v=1772567364045 "Graph of future (projected) profit of the company Passage Bio Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Passage Bio, Inc. is a gene therapy company focused on developing treatments for rare monogenic diseases of the central nervous system (CNS). This chart shows revenue projections for the neuroscience sector. It reflects the high hopes for gene therapy as a way to dramatically transform the lives of patients with severe diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772567364115 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Passage Bio develops gene therapy for rare CNS diseases. For companies like these, the market's overall profit forecast is an indicator of capital availability. During periods of economic optimism, as reflected in the chart, venture capitalists and funds increasingly fund biotech companies, which is critical for the continued development of these companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772567364183 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Passage Bio Inc.
Passage Bio is a biotech company specializing in gene therapy for rare CNS diseases. Currently in the clinical stage, it has no sales revenue. P/S will become a key metric after the approval of its first drug, reflecting its market potential.
P/S market segment - Neuro
Passage Bio is a genetic medicine company focused on developing life-changing treatments for rare monogenic diseases of the central nervous system (CNS). Their valuation reflects the potential of gene therapy. This chart shows the market's confidence in their scientific approach and ability to commercialize complex gene therapies.
P/S of the market as a whole
Passage Bio is a biotech company developing gene therapy for rare diseases of the central nervous system. The company has no commercial revenue. This chart, showing how the market values real revenue, clearly demonstrates that Passage Bio is a venture bet on the complex but promising field of gene therapy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Passage Bio Inc.
Passage Bio is a biotech company specializing in gene therapy for rare monogenic diseases of the central nervous system. This chart reflects investor expectations for future revenue from these complex and expensive treatments, which have the potential to dramatically change the lives of patients with severe genetic disorders.
%20P%2FS%20Passage%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Passage-Bio-Inc.&v=1772567364304 "The graph of the company's future (projected) P/S Passage Bio Inc.")
Future (projected) P/S of the market segment - Neuro
Passage Bio, Inc. is a gene therapy company focused on developing treatments for rare monogenic diseases of the central nervous system (CNS). This chart shows how the market views the future potential of its complex and expensive treatments. It compares it to other companies in the neuroscience sector, highlighting the risks and promises of gene therapy.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772567364342 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Passage Bio is a company developing gene therapy for rare diseases of the central nervous system. This is at the cutting edge of science, with high risks and potentially enormous rewards. This chart illustrates general expectations for future revenue, and PASG shows how investors view the potential of gene therapy to transform medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772567364391 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Passage Bio Inc.
Passage Bio, Inc. is a clinical-stage gene therapy company specializing in the treatment of rare monogenic diseases of the central nervous system (CNS). Because its drugs are in development, the company has no sales revenue. Any revenue shown in this chart may be related to collaboration fees.
Sales of companies in the market segment - Neuro
Passage Bio is a biotech company developing gene therapies for rare CNS diseases. At this stage, it likely has no product revenue. The graph may reflect revenue from collaborations with partners, a key source of funding for its expensive clinical programs.
Overall market sales
Passage Bio is a biotech company focused on gene therapy for rare diseases of the central nervous system. Its success depends entirely on progress in clinical trials. This market summary chart does not apply to Passage Bio, whose mission and value are driven by science, not macroeconomics.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Passage Bio Inc.
Passage Bio is a biopharmaceutical company developing gene therapies for rare diseases of the central nervous system. Its revenue forecast is dependent on the success of clinical trials. This chart reflects analysts' speculative expectations for the commercial potential of its cutting-edge treatments.
%20sales%20of%20the%20company%20Passage%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Passage-Bio-Inc.&v=1772567364498 "Schedule of future (projected) sales of the company Passage Bio Inc.")
Future (projected) sales of companies in the market segment - Neuro
Passage Bio is a gene therapy company focused on treating rare diseases of the central nervous system. This chart shows projected revenue for the entire neuroscience segment. It provides an estimate of the size of the CNS gene therapy market analysts see, which is critical to Passage Bio's commercial prospects.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772567364546 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Passage Bio is a biotech company developing gene therapy for rare diseases of the central nervous system. Its success depends entirely on the results of clinical trials. This graph of overall market expectations reflects the investment climate, which is critical for funding expensive and long-term gene therapy projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772567364637 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Passage Bio Inc.
Passage Bio is a clinical-stage gene therapy company specializing in the treatment of rare diseases of the central nervous system. This chart reflects its current research focus and shows the extent of its investment in the science on which its future depends.
Market segment marginality - Neuro
Passage Bio is a genetic medicine company focused on developing transformative treatments for rare monogenic diseases of the central nervous system. This chart shows the average profit margin for gene therapy companies. It serves as a benchmark for assessing the potential profitability of Passage Bio's products in the orphan disease market.
Market marginality as a whole
Passage Bio, Inc. is a company specializing in gene therapy for rare diseases of the central nervous system. Its future depends on the success of its clinical programs. This gross margin chart has no bearing on Passage Bio's valuation, which is a bet that its unique scientific approaches will prove effective and safe.
Employees in the company, segment and market as a whole
Number of employees in the company Passage Bio Inc.
Passage Bio is a biotech company developing gene therapies for rare diseases of the central nervous system. The growth of its scientific and clinical teams, visible in the graph, is a direct indicator of the progress of its complex and expensive research programs.
Share of the company's employees Passage Bio Inc. within the market segment - Neuro
Passage Bio is a genetic medicine company focused on developing transformative therapies for rare monogenic diseases of the central nervous system (CNS). This chart highlights its scientific expertise. It reflects the percentage of leading geneticists and neuroscientists working on life-saving gene therapies that Passage Bio brings together.
Number of employees in the market segment - Neuro
Passage Bio, Inc. is a biopharmaceutical company specializing in gene therapy for rare diseases of the central nervous system. This chart illustrates employment in neuroscience. The growing number of scientists in this field reflects breakthroughs in genetic engineering and the massive investment in finding treatments for previously untreatable neurological disorders.
Number of employees in the market as a whole
Passage Bio, Inc. is a company focused on developing gene therapies for the treatment of rare monogenic diseases of the central nervous system. This is a complex and capital-intensive field. This chart shows the overall employment landscape where biotech companies like Passage Bio are contributing to the development of cutting-edge medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Passage Bio Inc. (PASG)
Passage Bio is a company developing gene therapies for rare CNS diseases. For a clinical-stage biotech, this chart is a pure reflection of its "intellectual capital." The company doesn't have mass production; its value lies in its scientific platform and development pipeline. The chart shows how highly the market values the potential of these future drugs, developed by a small team of scientists.
%20of%20the%20company%20Passage%20Bio%20Inc.%20(PASG)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Passage-Bio-Inc.-PASG&v=1772567365182 "Chart of market capitalization per employee (in thousands of dollars) of the company Passage Bio Inc. (PASG)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Passage Bio is a biotech company specializing in gene therapy for rare diseases of the central nervous system. Its high market cap per employee is typical for this industry and reflects the enormous potential market if successful. This is a bet by investors that a small team of scientists can create a breakthrough drug.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772567365242 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Passage Bio is a company developing gene therapies for rare diseases of the central nervous system. This is an extremely complex and expensive area of research. This chart reflects investors' hopes that the team of scientists will succeed where many have failed and create life-saving treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772567365286 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Passage Bio Inc. (PASG)
Passage Bio is a clinical-stage biotech company focused on gene therapy for rare CNS diseases (such as dementia). It's an R&D business. This negative graph shows how much capital is spent on each scientist working on these highly complex and expensive drugs.
%20Chart%20Passage%20Bio%20Inc.%20(PASG)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Passage-Bio-Inc.-PASG&v=1772567365345 "Company Profit Per Employee (in thousands of dollars) Chart Passage Bio Inc. (PASG)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Passage Bio is a genetic medicine company developing treatments for rare monogenic diseases of the central nervous system. In the field of gene therapy, this chart reflects the value of their research portfolio. It shows the potential profit from a single successful drug capable of changing patients' lives, which is a measure of the effectiveness of their research team.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772567365385 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Passage Bio, Inc. is a company developing gene therapy for rare neurological diseases of the central nervous system. This is one of the most complex and expensive areas of R&D. This chart demonstrates the enormous investment required per employee (scientist, physician) to develop and test treatments that could change patients' lives.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772567365422 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Passage Bio Inc. (PASG)
Passage Bio is a biotech company specializing in gene therapy. This chart doesn't reflect commercial viability during clinical trials. It illustrates the level of investment in research. If even one drug is successful, revenue per employee will skyrocket.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Passage-Bio-Inc.-PASG&v=1772567365507 "Sales chart per company employee Passage Bio Inc. (PASG)")
Sales per employee in the market segment - Neuro
Passage Bio (PASG) is a gene therapy company focused on treating rare neurological diseases (CNS). This chart shows average revenue per employee in the pharmaceutical segment. For Passage Bio, which is in clinical development, comparing it to this benchmark (zero) highlights their focus on developing complex treatments rather than on current sales productivity.
Sales per employee for the market as a whole
Passage Bio (PASG) is a clinical-stage biotech company focused on CNS gene therapy. Like other R&D companies (RLYB, XCUR), it has no revenue. This metric is zero. It will only become meaningful if clinical trials are successful and FDA approval is obtained, paving the way for commercialization of their developments.
Short shares by company, segment and market as a whole
Shares shorted by company Passage Bio Inc. (PASG)
Passage Bio is a biotech company specializing in gene therapy for rare neurological diseases. This is one of the riskiest areas in biotech. This chart shows the odds on the failure of their clinical trials. The bears are confident their therapy will be either ineffective or unsafe, leading to the company's demise.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Passage-Bio-Inc.-PASG&v=1772567365613 "Short Shares Chart for the Company Passage Bio Inc. (PASG)")
Shares shorted by market segment - Neuro
Passage Bio (PASG) operates at the intersection of two of the riskiest sectors: gene therapy and neuroscience. This chart shows the pessimism across the sector. The surge in short positions across the sector is a bet that this entire scientific platform is a capital "graveyard." Investors are skeptical of brain gene therapy and are betting en masse on the failure of clinical trials.
Shares shorted by the overall market
Passage Bio (PASG) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like PASG in order to move into safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Passage Bio Inc. (PASG)
Passage Bio is a biotech company developing gene therapy for rare diseases of the central nervous system. This is an extremely complex and expensive process. This oscillator is the "pulse" of investors' hopes. It can sharply "heat up" to peak values on positive data and just as quickly "cool down" at the slightest sign of research failure.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Passage-Bio-Inc.-PASG&v=1772567365752 "RSI 14 indicator chart for the company's stock Passage Bio Inc. (PASG)")
RSI 14 Market Segment - Neuro
Passage Bio is a biotech company focused on developing gene therapies for the treatment of rare and severe neurological diseases (CNS). This R&D activity has high risk and potential. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Passage Bio compares to that.
RSI 14 for the overall market
Passage Bio (PASG) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the opportunity to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PASG (Passage Bio Inc.)
Passage Bio is a biotech company focused on developing gene therapies (AAVs) for the treatment of rare and severe neurological diseases (CNS). This chart shows the speculative average 12-month price target from analysts, which is almost entirely based on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PASG-Passage-Bio-Inc.&v=1772567365825 "A chart showing analyst consensus forecasts for the expected stock price. PASG (Passage Bio Inc.)")
The difference between the consensus estimate and the actual stock price PASG (Passage Bio Inc.)
Passage Bio is a biotech company focused on developing gene therapies (AAVs) for the treatment of rare and severe CNS (brain) diseases. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this complex R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PASG-Passage-Bio-Inc.&v=1772567365859 "A chart showing the difference between the consensus forecast and the actual stock price. PASG (Passage Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Passage Bio is a biotech company focused on "one-shot gene therapy" for the treatment of rare and devastating brain (CNS) diseases. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe breakthroughs in the treatment of genetic brain diseases are possible.
Analysts' consensus forecast for the overall market share price
Passage Bio is a biotech company specializing in gene therapy development for rare neurological diseases (CNS). This chart shows the overall market "risk appetite." For Passage Bio, operating in the most complex area of medicine, overall market optimism is critical to funding long-term, expensive trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Passage Bio Inc.
Passage Bio is a biotech company focused on one of the most challenging targets: gene therapy for the brain. They are developing AAV therapies for rare neurological diseases (dementia, Parkinson's). This chart is a pure indicator of their (very risky) R&D. Its dynamics depend entirely on their clinical data and their ability to hack the brain.
AKIMA Market Segment Index - Neuro
Passage Bio (PASG) is a gene therapy company specializing in the treatment of rare monogenic CNS (central nervous system) diseases, such as dementia and seizure disorders in children. The chart shows the segment average. It helps investors assess how PASG's risks in this complex field compare to the average for the neuroscience sector.
The AKIM Index for the overall market
Passage Bio is a genetic medicine company developing treatments for central nervous system disorders. Its focus is on gene delivery to the brain. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this scientific platform.
